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Some compounds belonging to the family of the diarylsulfony-
lureas (DSU) show significant antitumour activity in in vitro
and in vivo assays (Howbert et al, 1990; Houghton and
Houghton, 1996). One of the main interests of DSU is that the
mechanism by which they exert their toxic effect on tumour
cells remains unknown, and seems to be different from the
mechanisms described for other antitumour cytotoxic drugs
(Sosinski et al, 1993). Until now, the only putative cellular
target that has been proposed for these compounds is a protein
of 34 kD with a NADH oxidase activity that can be inhibited
by thiol reagents such as the N-ethyl-maleimide (NEM). This
protein is associated with the membranes of tumour cells and is
also found in the serum of cancer patients but not in that of
normal donors (Kim et al, 1997). Morré et al have demonstrated
that the active sulfonylurea LY181984 binds to and inhibits
the activity of this enzyme (Morre et al, 1995b,d). On the basis
of theoretic structure-activity COMFA studies, we designed,
synthesized and tested in in vitro antitumour assays several
analogues and derivatives of DSU (Gil et al, 1999; Martínez-
Merino et al, 2000) in the hope of finding new compounds
with improved antitumoural activity and reduced toxicity. Based
on the results obtained in that work we have designed and
synthesized several benzo(b)thiophenesulfonamide 1,1-dioxide
derivatives (BTS) some of which are structurally related with
DSU. 
Here we describe the effect of 6 BTS on a NADH oxidase
activity found in plasma membranes and conditioned culture
medium of CCRF-CEM cells whose kinetic properties correspond
to those of the protein described by Morré et al, in other tumour
cells as a putative target of DSU. 
MATERIALS AND METHODS 
Cell culture 
CCRF-CEM cells (ATCC, Manassas, VA) were grown in RPMI
1640 medium (Gibco, Grand Island, NY) supplemented with 10%
fetal calf serum, glutamine (2 mM) and gentamicyn (0.1 mg ml–1).
Primary rat vascular smooth muscle cells were isolated and
cultured according to Bacakova et al (1997). 
Candidate antineoplastic drugs 
The compounds used in this work were synthesized as described
(Martínez-Merino et al, 2000). Candidate drugs were initially
dissolved in DMSO at 0.1 M, and then diluted with complete
culture medium to the final concentrations indicated in every
assay. 
Cytotoxicity assay 
CCRF-CEM cells were cultured in the presence of the compounds
to be tested (100 µ M) for the indicated periods of time. The cyto-
toxic effect was determined by following spectrophotometrically
the release of cytoplasmic lactate dehydrogenase (LDH) to the
culture medium with a Cytotoxicity Detection Kit (Roche,
Indianapolis, IN). The percentage of cytotoxicity was calculated as
follows: [(experimental release – spontaneous release)/(maximum
release – spontaneous release)] × 100. Spontaneous release and
maximum release were obtained by incubating the cells alone or
with a 0.1% Triton x-100 solution respectively. 
NADH oxidase activity measurement 
NADH oxidase activity was studied in samples of isolated plasma
membranes and culture supernatants of CCRF-CEM cells
following the method described by Morré et al (1995c) with minor
modifications. Plasma membranes were isolated by aqueous 2-
phase partition (Morre et al, 1995c). Conditioned medium was
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obtained from 24 hour cultures (initial cell density of 106 cells ml–1)
by centrifugation for 20 minutes at 2500 rpm. NADH oxidase
activity was determined at 37˚C as the disappearance of NADH
measured at 340 nm in a reaction mixture containing 25 mM Tris-
Mes buffer (pH 7.2), 1 mM KCN and the indicated concentrations
of NADH (Sigma, St Louis, MO). Absorbance was recorded 30
seconds and 5 minutes after adding NADH, and a millimolar
extinction coefficient of 6.22 was used to calculate the rate of
NADH disappearance. Compounds to be tested as inhibitors were
added at final concentrations ranging from 100 to 0.1 µ M.
Percentages of inhibition were calculated by the formula: [1-
(enzymatic activity in the presence of inhibitor/enzymatic activity
in the absence of inhibitor)] × 100. 
RESULTS 
The structure of BTS included in this study is shown in Figure 1.
We chose the acute lymphoblastic T leukaemia cell line CCRF-
CEM as a model to investigate the activity of these compounds on
tumour cells for 2 main reasons. First, because it has been used for
the screening of many candidate antitumour drugs, including a
high number of DSU (Howbert et al, 1990), and therefore the use
of this cell line allows us to compare our results with those data.
Second, because these cells have been also used to characterize
with some detail the process of cell death in response to different
antineoplasic drugs (Huschtscha et al, 1996). To test the cytotoxic
activity of BTS compounds on CCRF-CEM cells we performed a
series of in vitro cytotoxicity assays as described in Materials and
methods. As shown in Figure 2, all tested BTS except the
compound D displayed a clear cytotoxic activity on CCRF-CEM
cells that is basically completed 48 hours after drug addition. As
we said before, until now the only cell target proposed for DSU is
a tumour-specific NADH oxidase enzyme described by Morré et al
in HeLa and other tumour, whose activity can be inhibited by DSU
and thiol reagents (Morre et al, 1995a,c,d). As the BTS used in this
work were designed on the basis of experimental results obtained
with DSU, and some BTS are structurally closely related with
them, it appeared interesting to investigate if these compounds
also exert some effect in this NADH oxidase. 
As a first step we performed some experiments in order to
investigate if a thiol reagent-sensitive NADH oxidase activity
could be detected in CCRF-CEM cell membranes and super-
natants. As shown in Figures 3A and B, a clear activity could be
detected in both CCRF-CEM membranes and conditioned culture
medium, respectively. The KM values obtained in both cases were
basically identical (27 and 28 µ M), and coincide with those
obtained by Morré et al in membranes and culture supernatants
from other tumour cells (Morre et al, 1995d). Moreover, thiol
reagents such as NEM can inhibit this activity (data not shown).
All these data strongly suggest that the enzyme responsible for this
activity in samples from CCRF-CEM cells corresponds to that
previously described by Morré et al in other tumour cells. It has
been previously reported that this thiol reagent-sensitive NADH
activity is specific of tumour cells and not detectable in normal
cells (Morre et al, 1995a,d). In agreement with that, we failed to
detect this activity in conditioned culture medium from normal rat
smooth muscle cells (data not shown). As reported for other
primary normal cells (Morre et al, 1995a,d), only a thiol reagent-
resistant, non tumour-specific NADH oxidase activity was
detected in smooth muscle cell supernatants. 
Finally, to test if the newly synthesized compounds were able to
inhibit the NADH oxidase activity characterized in CCRF-CEM
cells, enzymatic assays were repeated with samples of plasma
membranes and culture supernatants in the presence of NADH
0.15 mM and all the compounds investigated at doses ranging from
0.1 to 100 µ M. As depicted in Figures 4A and B, the 5 compounds
that previously showed cytotoxic activity on CCRF-CEM cells
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Figure 3 Kinetics of NADH oxidase activity found in membrane extracts 
(A) and conditioned cultured medium (B) of CCRF-CEM cells. The insets
show the calculated KM values. Means ± SD derived from 3 independent
experiments each performed in triplicate are presented 
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Figure 2 Determination of the cytotoxic effect of 6 BTS on CCRF-CEM
cells. Cells were incubated in the presence of every compound (100 µ M) for
the indicated periods of time. Culture supernatants were collected and cell
death quantification was performed by the measurement of the LDH
enzymatic activity released from damaged cells to the culture medium, as
described in material and methods. Values represent means ±SD derived
from 3 independent experiments each performed in quadruplicate 
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(Figure 2), also inhibited in a dose-dependent fashion the NADH
oxidase studied. The levels of inhibition reached at 100 µ M were
similar or higher than those obtained with NEM, indicating that
the residual activity corresponds to the non-tumour-specific, thiol
reagent-resistant activity also found in normal cells. Interestingly,
compound D, that is the reduced derivative of compound C and
showed no cytotoxicity on CCRF-CEM cells, also lacked any
inhibitory activity on the enzymatic assay, suggesting that both
effects could be related. 
DISCUSSION 
In this work we described the effect of new BTS derivatives in
leukaemic CCRF-CEM cells. We found a clear correlation
between the cytotoxic effect of the compounds tested and their
ability to inhibit an NADH oxidase located in the membrane of
these and other tumour cells. It is very significant that the
compound D, structurally very close to other compounds tested,
was inactive both in the cytotoxicity and the enzymatic assays.
These data suggest that the inhibition of this enzyme might play a
role in the cytotoxic effect of the tested BTS. The described
NADH oxidase activity most probably corresponds to the one
previously described by Morré et al (1995c). This enzyme, whose
physiologic function is unknown, has been proposed to be the
target of DSU (Morre et al, 1995d) and other cytotoxic drugs such
as capsaicin (Morre et al, 1995a), adriamicyn (Morre et al, 1997)
and anticancer quassinoids (Morre et al, 1998). The elucidation of
the function of this enzyme remains as the key to understand its
role in the effect of BTS and other cytotoxic drugs. 
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Figure 4 BTS inhibits the tumour-specific NADH oxidase activity of CCRF-
CEM cell membranes (A) and culture supernatants (B). NADH oxidase
activity in samples of membrane extracts and culture supernatants in the
presence of NADH (0.15 mM) and BTS derivatives (100, 10.1 and 0.1 µ m)
was determined as described in Materials and methods. Percentages of
inhibition were calculated as described in Materials and methods. Columns
and error bars represent means and standard deviations from
3 independent experiments each performed in triplicate